Chronic Lower Back Pain Therapeutics Market Size in the 7MM was approximately USD 6,071 million in 2023, estimates DelveInsight

CLBP companies are Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma LP, BioDelivery Sciences International, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc., Kolon Life Science, Eliem Therapeutics, Allodynic Therapeutics, Sollis Therapeutics, Medtronic Spinal and Biologics, Frontier Biotechnologies, DiscGenics Inc., Pfizer, Persica Pharmaceuticals, BioRestorative Therapies, Vertanical GmbH, Stayble Therapeutics, SpineThera, and others.
In 2023, the CLBP market across the seven major markets (7MM) was led by the United States, with a value of about USD 4.2 billion, and it is projected to grow at a CAGR of around 4%. The patient burden is also high, with roughly 68 million diagnosed prevalent cases in the 7MM. Despite this, there are no therapies specifically approved for CLBP, highlighting a significant unmet medical need.

Current treatment mainly focuses on symptom management. Opioids such as Xtampza ER (oxycodone) and BELBUCA dominate the market, accounting for the largest share (nearly USD 3 billion in 2023). Other commonly used options include NSAIDs, antidepressants, and anticonvulsants.

Market growth is being driven by an aging population, sedentary lifestyles, increased stress, and age-related spinal degeneration, along with improvements in diagnostics and treatment approaches. There is strong demand for more effective and safer long-term therapies.

An important emerging therapy is SP-102 (SEMDEXA) by Scilex Pharmaceuticals, a non-opioid corticosteroid gel injection in development for lumbar radicular pain (sciatica). With a potential US launch expected around 2025, it could significantly reshape the CLBP treatment landscape by offering an alternative to opioid-based pain management.

Request for a Free Sample Report @ [https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=apr]

DelveInsight's "Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Chronic Lower Back Pain, historical and forecasted epidemiology as well as the Chronic Lower Back Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Chronic Lower Back Pain market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Chronic Lower Back Pain market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Chronic Lower Back Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Chronic Lower Back Pain market.

Chronic Lower Back Pain Overview

Chronic low back pain (CLBP) is pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain. Low back pain is widespread and likely to affect everyone at one point. The exact cause of lower back pain is not found yet. Lower back pain that is long-term (for more than 3 months) is called chronic lower back pain. This condition might originate from an injury, disease, or stress on different body structures. The pain may vary significantly and be felt as bone pain, nerve pain, or muscle pain, and its intensity ranges from mild to severe. Chronic lower back pain is the second leading cause of disability worldwide, being a major welfare and economic problem. The prevalence of chronic lower back pain in adults has increased significantly in the last decade and is continuously increasing vividly in the aging population.

Learn more about Chronic Lower Back Pain treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Chronic Lower Back Pain Market Outlook

Chronic Lower Back Pain (CLBP) is a complex and highly individualized condition, requiring tailored treatment plans based on each patient's specific disease process and pain profile. Multiple drug classes with distinct mechanisms of action are used to target different aspects of pain, while patient-specific factors are considered to improve adherence and outcomes.

About 80-90% of low back pain cases arise from mechanical causes such as degenerative disc or joint disease, vertebral fractures, and deformities, while neurogenic, inflammatory, and other causes make up the remainder. Early pharmacologic treatment is typically aligned with the underlying cause, but as pain becomes chronic, broader, multimodal strategies are often needed due to reduced effectiveness of targeted therapies. In inflammatory cases, treatment includes NSAIDs, corticosteroids, and DMARDs for conditions like rheumatoid arthritis and ankylosing spondylitis.

For severe, persistent pain, opioids such as Xtampza and BELBUCA are US FDA-approved for long-term, around-the-clock use when alternatives are inadequate. Emerging therapies include Rexlemestrocel-L (MPC-06-ID) and Cebranopadol (TRN-228).

The CLBP therapeutics market in the 7MM was about USD 6,071 million in 2023 and is projected to grow at a 3.7% CAGR. The US held 69% of the market, Spain USD 312 million, Italy ~USD 158 million, and Japan ~USD 866 million (14%). Upcoming launches like SEMDEXA (SP-102) may further shift market dynamics.

Explore more about Chronic Lower Back Pain Epidemiology @ CLBP Market Dynamics and Trends [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Chronic Lower Back Pain Pipeline Development Activities

Rexlemestrocel-L (MPC-06-ID) - Mesoblast/Grunenthal

Rexlemestrocel-L is an allogeneic mesenchymal precursor cell therapy being developed for Chronic Lower Back Pain (CLBP) linked to degenerative disc disease. It targets patients who no longer respond to conservative care, including those who have failed epidural steroid injections and are otherwise facing invasive surgery. In February 2023, the therapy received RMAT designation from the US FDA's OTAT for CLBP associated with disc degeneration when delivered with hyaluronic acid (HA) into the lumbar disc.

Results from the Phase III MSBDR003 trial in the US and Australia (reported in 2021) showed durable pain relief but did not meet the primary endpoint between groups. Following data analysis, Mesoblast launched a new confirmatory Phase III trial in the US, designed to support potential approvals in both the US and Europe. This study, evaluating a single intradiscal injection of rexlemestrocel-L+HA versus control, is expected to conclude by October 2026.

Semdexa (SP-102) - Scilex Holding Company

Semdexa (SP-102) is a non-opioid corticosteroid gel injection in development for lumbar radicular pain/sciatica. Its formulation avoids neurotoxic preservatives and particulates, potentially offering improved safety over commonly used injected steroids. The drug received FDA Fast Track designation in January 2018.

Backed by patent protection until 2036, SP-102 met Phase III endpoints in early 2022. In late 2023, the FDA aligned on the NDA pathway, and a final Phase III safety study is underway in 2024. In July 2024, Scilex's subsidiary Semnur Pharmaceuticals announced a planned merger with Denali Capital Acquisition Corp., valuing Semnur at up to USD 2.0 billion, with up to USD 40 million in expected cash at closing to support SP-102's continued development.

Do you know how emerging drug launch will be impacting the Acoustic Neuroma market CAGR? Download sample report @ Chronic Lower Back Pain Companies and Manufacturers [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Chronic Lower Back Pain Drugs Uptake

Chronic Lower Back Pain Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Chronic Lower Back Pain market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

* Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
* Semdexa (SP-102): Scilex Holding
* Cymbalta (Duloxetine): Eli Lilly and Company
* Hysingla ER: Purdue Pharma LP
* Xtampza: Collegium Pharmaceutical
* Butrans (buprenorphine): Purdue Pharma
* Belbuca: BioDelivery Sciences International
* Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited
* Semdexa (SP-102): Scilex Holding
* AMG0103: AnGes MG, Inc.
* KLS-2031: Kolon Life Science
* ETX-810: Eliem Therapeutics
* And many others.

Chronic Lower Back Pain Therapeutics Assessment

Major key companies are working proactively in the Chronic Lower Back Pain Therapeutics market to develop novel therapies which will drive the Chronic Lower Back Pain treatment markets in the upcoming years are Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma LP, BioDelivery Sciences International, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc., Kolon Life Science, Eliem Therapeutics, Allodynic Therapeutics, Sollis Therapeutics, Medtronic Spinal and Biologics, Frontier Biotechnologies, DiscGenics Inc., Pfizer, Persica Pharmaceuticals, BioRestorative Therapies, Vertanical GmbH, Stayble Therapeutics, SpineThera, and others.

Learn more about the emerging therapies & key companies @ Chronic Lower Back Pain Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Chronic Lower Back Pain Report Key Insights

1. Chronic Lower Back Pain Patient Population

2. Chronic Lower Back Pain Market Size and Trends

3. Key Cross Competition in the Chronic Lower Back Pain Market

4. Chronic Lower Back Pain Market Dynamics (Key Drivers and Barriers)

5. Chronic Lower Back Pain Market Opportunities

6. Chronic Lower Back Pain Therapeutic Approaches

7. Chronic Lower Back Pain Pipeline Analysis

8. Chronic Lower Back Pain Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Chronic Lower Back Pain Market

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-lower-back-pain-therapeutics-market-size-in-the-7mm-was-approximately-usd-6071-million-in-2023-estimates-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.